UK Community Advisory Board (UK-CAB)
Email | |
  • JOIN THE NETWORK

    • UK-CAB 48: Hepatitis C co-infection

    07/11/2013 Alison Neathey
    Off
    Meetings

    PROGRAMME

    09.30 – 09.45 Registration, refreshments and expenses
    09.45 – 10.00 Welcome, introductions, UKCAB updates
    10.00 – 10.30 UK-CAB treatment activism feedback – speakers tbc
    10.30 – 11.00 Introduction to Hepatitis C  – Robert James
    11.00 – 11.15 Break
    11.15 – 12.30 HCV monitoring, treatment and studies updates – Dr Graham Cooke, Imperial Hospital
    12.30 – 14.00 Lunch
    14.00 – 15.15 HCV self-management – Paula Mcfayden, Waverley Care
    15.15 – 15.30 Break
    15.30 – 16.00 POPPY study update  – Alan Winston, St Mary’s Hospital
    16.00 – 16.30 Conference feedback: EACS – Silvia Petretti UKCAB AOB
    16.30 Meeting close

    Background reading

    The following reading is included as preparation for this meeting.

    (1) UK-CAB Training

    Please see the online programme – this will be helpful for the feedback session.

    (2) Hepatitis C 

    Guide to HIV and HCV coinfection (i-Base)

    This guide is selected as pre-reading because the language is non-technical and it is very up-to-date on treatment (published November 2013).  If this is too long to read all of it, please see these sections.
    (3) The POPPY Study (HIV and ageing)
    See the information on the study design and endpoints on this HIV and Ageing study from the clinicaltrials.gov listing:

    Financial support

    The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

    The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

    We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

    For a list of companies that support the UK-CAB please see the “about us” page.

    Meetings
    Meetings